Rasagiline (Azilect) - Neuroprotection for Macula-off Retinal Detachment
Status:
Terminated
Trial end date:
2018-12-31
Target enrollment:
Participant gender:
Summary
This randomised, double-blind, placebo-controlled clinical trial investigates the
neuroprotective effect of rasagiline in patients suffering from a retinal detachment
affecting central vision. Based on results from a study in mice suffering from retinal
degeneration, the investigators hypothesize that rasagiline delays neurodegeneration in the
retina and improves visual acuity outcomes after retinal detachment surgery. Rasagiline is a
second-generation propargylamine with neuroprotective properties modulating the
caspase-dependent pathway of programmed cell death.